Gabriel Silver (Senior Therapeutic Strategy Manager at Novotech)
ArticleThe future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.